Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 12/2017

01-12-2017 | Review article

Pancreatic ductal adenocarcinoma: metastatic disease

Authors: A. J. Muñoz Martín, J. Adeva, J. Martínez-Galán, J. J. Reina, M. Hidalgo

Published in: Clinical and Translational Oncology | Issue 12/2017

Login to get access

Abstract

The treatment of choice of metastatic PADC is systemic chemotherapy. In the last decade, there have been significant advances in this area. New combination poli-chemotherapy schemes have shown a significant increase in overall survival and progression-free survival without impairing quality of life. In addition, the value of second-line chemotherapy treatment has consolidated and a new concept called “therapeutic sequencing” has also emerged. The aim of this article is to review the different therapeutic options in metastatic PDAC based on patient’s characteristics.
Literature
1.
2.
Hidalgo M, Cascinu S, Kleeff J, Labianca R, Löhr J, Neoptolemos J, et al. Addressing the challenges of pancreatic cancer: future directions for improving outcomes. Pancreatology. 2015;15:8–18.CrossRefPubMed
3.
Sener SF, Fremgen A, Menck HR, Winchester D. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985–1995, using the National Cancer Database. J Am Coll Surg. 1999;189:1–7.CrossRefPubMed
4.
Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis. 2001;33:139–44.CrossRefPubMed
5.
Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.CrossRefPubMed
6.
Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703.CrossRef
7.
Peixoto RD, Ho M, Renouf DJ, Lim HJ, Gill S, Ruan JY, et al. Eligibility of metastatic pancreatic cancer patients for first-line palliative intent nab-paclitaxel plus gemcitabine versus FOLFIRINOX. Am J Clin Oncol. 2015. doi:10.​1097/​COC.​0000000000000193​.
8.
Thota R, Pauff JM, Berlin JD. Treatment of metastatic pancreatic adenocarcinoma: a review. Oncology (Williston Park). 2014;28:70–4.
9.
10.
Chen YG, Pan HH, Dai MS, Kin C, Lu CS, Chang PY, et al. Impact of comorbidity and age on determinants therapeutic strategies in advanced pancreatic head cancer patients with obstructive jaundices. Medicine (Baltimore). 2015;94:e1298.CrossRef
11.
Venook AP, Egorin MJ, Rosner GL, Hollis D, Mani S, Hawkins M, et al. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: cancer and Leukemia Group B 9565. J Clin Oncol. 2000;18:2780–7.CrossRefPubMed
12.
Rothenberg ML, Meropol NJ, Poplin EA, Poplin EA, Van Cutsem E, Wadler S, et al. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol. 2001;19:3801–71.CrossRefPubMed
13.
Rahma OE, Duffy A, Liewehr DJ, Steinberg SM, Greten TF. Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. Ann Oncol. 2013;24:1972–9.CrossRefPubMedPubMedCentral
14.
Oettle H, Riess H, Stieler JM, Heil G, Shwaner I, Seraphin J, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol. 2014;32:2423–9.CrossRefPubMed
15.
Gill S, Ko YJ, Cripps C, Beaudoin A, Dhesy-Thind S, Zulfiqar M, et al. PANCREOX: a randomized phase 3 study of 5FU/LV with or without oxaliplatin for second-line advanced pancreatic cancer (APC) in patients (pts) who have received gemcitabine (GEM)-based chemotherapy (CT). J Clin Oncol. 2014;32:A4022.CrossRef
16.
Chen LT, Von Hoff DD, Li CP, Wang-Gillam A, Bodoky G, Dean AP, et al. Expanded analyses of napoli-1: phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy. J Clin Oncol. 2015; 33 S3.
17.
Hosein PJ, de Lima G, Pastorini VH, Gomez C, Macintyre J, Zayas G, Reis I, et al. A phase II trial of nab-paclitaxel as second-line therapy in patients with advanced pancreatic cancer. Am J Clin Oncol. 2013;36:151–6.CrossRefPubMed
18.
Bertocchi P, Abeni C, Meriggi F, Rota K, Rizzi A, Di Biasi B, Aroldi F, et al. Gemcitabine plus nab-paclitaxel as second-line and beyond treatment for metastatic pancreatic cancer: a single institution retrospective analysis. Rev Recent Clin Trials. 2015;10:142–5.CrossRefPubMed
19.
Petrelli F, Borgonovo K, Ghilardi M, Cabiddu M, Barni S. What else in gemcitabine-pretreated advanced pancreatic cancer? An update of second line therapies. Rev Recent Clin Trials. 2010;5:43–56.CrossRefPubMed
20.
Fortune BE, Li X, Kosuri KV, Weatherby LM, Thomas JP, Bekaii Saab TS. Fixed-dose-rate gemcitabine in combination with oxaliplatin in patients with metastatic pancreatic cancer refractory to standard-dose-rate gemcitabine: a single-institute study. Oncology. 2009;76:333–7.CrossRefPubMed
21.
Demols A, Peeters M, Polus M. Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer. 2006;94:481–5.CrossRefPubMedPubMedCentral
22.
Reni M, Cereda S, Mazza E, Passoni P. PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy. Am J Clin Oncol. 2008;31:145–50.CrossRefPubMed
23.
Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960–6.CrossRefPubMed
24.
Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24:5313–27.CrossRefPubMed
25.
Ducreaux M, AS Cuhna, Caramella C, Hollebecque A, Burtin D, Goéré D, et al. Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;5:v56–68.CrossRef
26.
Shah MA, Capanu M, Soff G, Asmis T, Kelsen DP. Risk factors for developing a new venous thromboembolism in ambulatory patients with non-hematologic malignancies and impact on survival for gastroesophageal malignancies. J Thromb Haemost. 2010;8:1702–92.CrossRefPubMed
27.
28.
29.
Di Maio M, Bria E, Banna GL, Puglisi F, Garssino MC, Lorusso DP. Prevention of chemotherapy-induced nausea and vomiting and the role of neurokinin 1 inhibitors: from guidelines to clinical practice in solid tumors. Anticancer Drugs. 2013;24:99–111.CrossRefPubMed
30.
Qi WX, Lin F, Sun YJ, Tang LN, Shen Z, Yao Y. Risk of venous and arterial thromboembolic events in cancer patients treated with gemcitabine: a systematic review and meta-analysis. Br J Clin Pharmacol. 2013;76:338–47.CrossRefPubMedPubMedCentral
31.
Giordiano G, Milella M, Lo Re G, Di Marco M, Melisi D, Passardi A, et al. Nab paclitaxel (Nab-P) and Gemcitabine (G) first line chemotherapy (CT) in metastatic pancreatic cancer (mPC) patients (pts) relapsed after adjuvant treatment (ADJ T): A “real life” study. J Clin Oncol. 2017;35(Suppl 4S):396. doi:10.​1200/​JCO.​2017.​35.​4_​suppl.​396.
Metadata
Title
Pancreatic ductal adenocarcinoma: metastatic disease
Authors
A. J. Muñoz Martín
J. Adeva
J. Martínez-Galán
J. J. Reina
M. Hidalgo
Publication date
01-12-2017
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 12/2017
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-017-1690-6

Other articles of this Issue 12/2017

Clinical and Translational Oncology 12/2017 Go to the issue

Research Article

Annual hazard rate of relapse of stage II and III colorectal cancer after primary therapy

Research Article

Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain

Research Article

Influence of ovarian cancer type I and type II microenvironment on the phenotype and function of monocyte-derived dendritic cells

Research Article

Bone marrow fibrosis at diagnosis predicts survival for primary acute myeloid leukemia

Research Article

Platelet–lymphocyte and neutrophil–lymphocyte ratios are prognostic but not predictive of response to abiraterone acetate in metastatic castration-resistant prostate cancer

Research Article

Overexpression of dishevelled 2 is involved in tumor metastasis and is associated with poor prognosis in hepatocellular carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits